CCM® has been used to treat over 4,000 patients and is currently available in the United States, Europe (obtained CE Mark in October 2016), China, Brazil, India and more than 40 other countries around the world.

* CCM® therapy sends precisely timed electrical pulses to the heart cells during the absolute refractory period of the beating cycle, just after the heart contracts, to improve systolic contraction of the heart.
* The Optimizer® Smart was granted Breakthrough Device designation by the FDA, and it is the first and only FDA-approved (March 2019) device in the United States, or elsewhere in the world, for the delivery of CCM® therapy.
* CCM® therapy, is a minimally invasive, implantable device, is the first therapy of its kind designed to strengthen the heart so it can contract more forcibly, allowing more oxygen-rich blood to reach the body.

**About CCM® Therapy**

We offer cardiac contractility modulation therapy to treat adults with moderate-to-severe chronic heart failure. CCM® delivers non-excitatory electrical signals to the right side of the intraventricular septum during the absolute refractory period of the ventricular contraction, and does not trigger a new action potential. CCM® signals are delivered by Impulse Dynamics’ Optimizer system (i.e. Optimizer IVs), which is an implantable pulse generator. This device is implanted in a minimally-invasive procedure under local anesthesia, typically in the right pectoral region. CCM® has been evaluated in patients with heart failure with reduced ejection fraction (HFrEF) In contrast to a pacemaker or a defibrillator, the system is designed to modulate the strength of contraction of the heart muscle rather than the rhythm. CCM® therapy is delivered at regular intervals throughout the day.